NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report report published on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock.

Several other equities analysts have also issued reports on NRXP. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. D. Boral Capital restated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a report on Monday, January 5th. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.75.

NRx Pharmaceuticals Stock Performance

NRXP stock opened at $2.27 on Thursday. The firm has a market cap of $67.19 million, a P/E ratio of -0.97 and a beta of 1.62. The firm’s fifty day moving average is $2.34 and its 200 day moving average is $2.73. NRx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $4.28.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $6.83 million. As a group, analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ethos Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Sjbenen Advisory LLC purchased a new stake in NRx Pharmaceuticals in the fourth quarter worth $41,000. One Wealth Management Investment & Advisory Services LLC raised its holdings in NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after purchasing an additional 12,950 shares in the last quarter. Two Sigma Investments LP raised its holdings in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.